HC Wainwright & Co. Assumes SAB Biotherapeutics at Buy, Announces Price Target of $10
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
HC Wainwright & Co. analyst Emily Bodnar assumes SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and announces Price Target of $10.
HC Wainwright & Co. analyst Emily Bodnar assumes SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and announces Price Target of $10.